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Resistance to Linezolid Caused by Modifications at Its Binding Site
on the Ribosome
Katherine S. Longa and Birte Vesterb
Department of Systems Biology and Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark,a and Department of
Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmarkb
Linezolid is an oxazolidinone antibiotic in clinical use for the treatment of serious infections of resistant Gram-positive bacteria.
It inhibits protein synthesis by binding to the peptidyl transferase center on the ribosome. Almost all known resistance mecha-
nisms involve small alterations to the linezolid binding site, so this review will therefore focus on the various changes that can
adversely affect drug binding and confer resistance. High-resolution structures of linezolid bound to the 50S ribosomal subunit
show that it binds in a deep cleft that is surrounded by 23S rRNA nucleotides. Mutation of 23S rRNA has for some time been es-
tablished as a linezolid resistance mechanism. Although ribosomal proteins L3 and L4 are located further away from the bound
drug, mutations in specific regions of these proteins are increasingly being associated with linezolid resistance. However, very
little evidence has been presented to confirm this. Furthermore, recent findings on the Cfr methyltransferase underscore the
modification of 23S rRNA as a highly effective and transferable form of linezolid resistance. On a positive note, detailed knowl-
edge of the linezolid binding site has facilitated the design of a new generation of oxazolidinones that show improved properties
against the known resistance mechanisms.
LINEZOLID
Linezolid (Fig. 1A) is a synthetic drug and a member of theoxazolidinone class of antibiotics. It acts as a protein synthesis
inhibitor by binding to the ribosomal peptidyl transferase center
(PTC) and stopping the growth of bacteria. Linezolid appeared on
the market in 2000 for treatment of serious infections caused by
Gram-positive bacteria resistant to other antibiotics, including
streptococci, vancomycin-resistant enterococci (VRE), and
methicillin-resistant Staphylococcus aureus (MRSA) (9). It is not
well suited for fighting Gram-negative pathogenic bacteria that
are intrinsically resistant due to efflux pumps that force linezolid
out of the cell faster than it can accumulate (1, 74). Linezolid is one
of the few truly new antibiotics that have been introduced inmany
years, as most newcomers are derivatives of existing drugs. The
development of new antibiotics is apparently not an attractive
business despite the expanding problem of antibiotic resistance in
pathogenic bacteria. At the introduction of linezolid, it was
claimed that there would be no cross-resistance to linezolid and
that resistance would be rare and difficult for the bacteria to de-
velop (20, 103), but resistance does appear (reviewed in references
61 and 85). Thisminireviewwill present in detail how several types
of modifications at the linezolid binding site on the ribosome can
cause resistance to linezolid and other oxazolidinones. The only
clear nonribosomal linezolid resistance mechanism reported is
related to mutations causing increased expression of ABC trans-
porter genes in Streptococcus pneumoniae (3, 19). It has also been
shown that Staphylococcus aureus possesses a gene for a major-
facilitator-superfamily-type multidrug efflux pump named LmrS
that is capable of extruding linezolid (21).
Although linezolid is currently the only oxazolidinone antibi-
otic approved for treatment of bacterial infections, other oxazo-
lidinones have been investigated and have entered development.
Some examples are eperezolid, which behaves similarly to lin-
ezolid (reviewed in reference 9) and posizolid (AZD2563) (98).
Some newer derivatives are tedizolid phosphate (previously
known as torezolid phosphate [TR-701]), an oxazolidinone drug
currently in phase III trials for acute bacterial skin and skin struc-
ture infections, including those caused by MRSA (http://www
.clinicaltrials.gov/ct2/show/NCT01170221?termtedizolid
&rank4) (79), and radezolid (RX-1741), which has completed
two phase II clinical trials, one for uncomplicated skin and skin-
structure infections and the other for community-acquired pneu-
monia (86). There is an obvious interest in developing a new gen-
eration of oxazolidinone derivatives which can overcome the
known resistancemechanisms. A recent paper (52) focused on the
structure-activity relationships (SAR) of oxazolidinones, includ-
ing some new derivatives, using a panel of clinical and laboratory-
derived S. aureus strains possessing ribosomal resistance muta-
tions or the Cfr methyltransferase gene. The data show that
improvement regarding the known resistancemechanisms is pos-
sible for oxazolidinone derivatives.
THE LINEZOLID BINDING SITE ON THE RIBOSOME
Although some of the first reports on linezolid claimed that it was
a unique drug with a unique mechanism of action, we now know
that the mechanism of action is similar to those of other antibiot-
ics binding to the PTC. The first indications of the exact binding
site of linezolid on the ribosome came in 1999 from studies of
resistance mutations in 23S rRNA and pointed to the PTC (41).
The PTC is in the middle of the 50S ribosomal subunit in the
bottom of the cleft where the 3= ends of aminoacyl-tRNA and
peptidyl-tRNA are positioned for peptide transfer (Fig. 1B andC).
Binding of linezolid to this area was subsequently supported by
other mutagenesis studies but could not be verified by antibiotic
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FIG 1 (A) The chemical structure of linezolid. (B) The E. coli 70S X-ray structure with 16S rRNA in orange, 30S ribosomal proteins in yellow, 23S rRNA in gray,
and 50S ribosomal proteins in blue (PDB file from reference 75). (C) A cutaway view of the large ribosomal subunit with a red circle at the PTC (PDB file from
reference 77). A P-site-bound tRNA is shown in magenta, and the PTC and peptide exit tunnel are indicated. (D and E) Close-up views of the linezolid binding
site made with the PyMOL software program. The coloring of nucleotides indicates first-layer (blue), second-layer (green), third-layer (orange), and outer-layer
(red) nucleotides with respect to linezolid. (D) The locations ofmutated nucleotides with respect to bound linezolid. First-layer nucleotides are shown in surface
representation. (E) The position of G2576with respect to linezolid. (F) Illustration of how parts of the L3 (in purple) and L4 (in green) ribosomal proteins extend
toward the PTCwhere linezolid (in red) is bound. Selected amino acids are marked with the corresponding S. aureus numbering. The coordinates are from PDB
file 3DLL (95).
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footprinting, a technique that has been used successfully to local-
ize ribosomal binding sites for other antibiotics. Cross-linking
studies with linezolid derivatives also pointed to a location at the
PTC (12, 46). In 2008, this site was confirmed by crystal structures
of linezolid bound to the 50S ribosomal subunit from the ar-
chaeon Haloarcula marismortui (36) and from the bacterium
Deinococcus radiodurans (95). The structures reveal that linezolid
binds to the A site of the PTC and interacts extensively with many
23S rRNA nucleotides in the neighborhood (Fig. 1D and E and
Fig. 2). The PTC is almost exclusively composed of RNA, and the
nucleotides in this region are phylogenetically highly conserved.
The many crystal structures of 50S subunit-antibiotic complexes
that have now been published also reveal that linezolid partially
shares its binding site with other antibiotics that inhibit protein
synthesis. Chloramphenicol, clindamycin, tiamulin, and strepto-
gramin A (plus bruceantin, homoharringtonine, and anisomycin,
which preferentially bind to eukaryotic and archaeal ribosomes)
all occupy overlapping sites with linezolid at the A site of the PTC
(original references and Protein Data Bank [PDB] identification
[ID] are in references 10, 14, and 94), where the aminoacyl moiety
of A-site tRNAhas to be positioned for successful peptide transfer.
This is underscored by the cross-resistance between linezolid and
other drugs binding to this region. Thus, linezolid binds to a com-
mon antibiotic site on the ribosome and acts by blocking precise
positioning of A-site tRNA in the PTC. The crystal structures have
also shown that the nucleotides in the PTC adapt to the binding of
antibiotics by slight changes in their relative positions, where es-
pecially nucleotide 2585 (Fig. 1D) seems very disposed to reposi-
tioning (95). The differences in modes of action of the antibiotics
must be ascribed to their overlapping but not identical binding
sites and how they affect neighboring nucleotides in combination
with their mode of access, affinity for the site, and association and
dissociation rate constants.
Knowledge of the molecular details of linezolid binding to the
PTC is highly advantageous for development of new oxazolidi-
none derivatives. It can indicate where there is room for drug
derivatization, suggest sites for additional interactions, and thus
facilitate the prediction of beneficial as well as detrimental inter-
actions. Finally, the structures can be used to suggest drug modi-
fications that will allow it to bind to the ribosome despite the
presence of resistance determinants (22). This approach has been
successfully exploited by the company Rib-X, who used knowl-
edge about linezolid and sparsomycin binding to the 50S ribo-
somal subunit to create new drugs from parts of these antibiotics
(86). They bridged and derivatized the two components, and one
example is the radezolid mentioned above, where one ring of the
linezolid (left side on Fig. 1A) is replaced and extended to obtain
additional interaction in the PTC. Another example is presented
by Trius Therapeutics, who modeled linezolid and tedizolid (pre-
viously known as torezolid [TR-700]) to the binding sites in the
PTC with and without a methylation at the C-8 position of the
adenine at position 2503 (52). This showed a better accommoda-
tion of TR-700 than linezolid in the presence of the methylation,
which is the resistance determinant mediated by the Cfr methyl-
transferase (described below).
RESISTANCE CAUSED BY 23S rRNA MUTATIONS
The linezolid binding site at the PTC is composed entirely of RNA,
and until recently, mutation of 23S rRNA was the only known
linezolid resistance mechanism. The binding pocket is lined with
FIG 2 Secondary structure of the peptidyl transferase loop of domain V of 23S rRNA (M. smegmatis sequence in E. coli numbering). The nucleotides that form
the linezolid binding pocket are indicated with black triangles. Nucleotide positions where mutations confer linezolid resistance are marked with yellow circles.
The nucleotides wheremutations have a significant effect on linezolidMIC (4-foldMIC increase) are in bold type, whereas those wheremutations have a small
to moderate effect on the linezolid MIC (4-fold or less MIC increase) are in regular type. The mutations and corresponding organisms are indicated with
two-letter abbreviations: Ec (E. coli), Sa (S. aureus), Se (S. epidermidis), Sh (S. haemolyticus), Sp (S. pneumoniae), Es (E. faecalis), Em (E. faecium), Ms (M.
smegmatis), Mt (M. tuberculosis), and Hh (H. halobium). Asterisks indicate mutations found in clinical isolates. Only mutations where some evidence or strong
indication of the mutation-resistance relationship has been published are marked on the figure (8, 19, 30, 41, 47, 50, 56, 59, 60, 62, 66, 69, 73, 97, 99, 100).
Minireview
February 2012 Volume 56 Number 2 aac.asm.org 605
 o
n
 M
arch 14, 2012 by TECH KNO
W
LEDG
E CTR O
F DENM
ARK
http://aac.asm
.org/
D
ow
nloaded from
 
the universally conserved nucleotides G2061, A2451, C2452,
A2503, U2504, G2505, U2506, and U2585, which interact directly
with linezolid (95) (Fig. 1D and 2). Strains selected for linezolid
resistance have mutations in 23S rRNA nucleotides G2061,
C2452, A2503,U2504, andG2505, which abut the bound linezolid
molecule (Fig. 1D and E and Table 1), but also at nucleotides that
are located more distally, such as A2062, G2447, A2453, C2499,
U2500, and G2576 (11, 19, 30, 41, 50, 51, 66, 69, 73) (Fig. 1D and
E and Table 1). The pattern of resistance is organism specific in
that the obtained mutation sites differ, with only little overlap,
between Halobacterium halobium, Escherichia coli, Enterococcus
faecalis, Enterococcus faecium, Mycobacterium smegmatis, Myco-
bacterium tuberculosis, S. aureus, and S. pneumoniae (Fig. 2 shows
detailed information). This specificity is likely related to single-
base identity differences in the RNA nucleotides that are more
distant from and do not directly abut the bound linezolid mole-
cule and variations in the fitness costs associated with specific
mutations in different organisms. The degree of resistance con-
ferred by themutations is not a simple function of the nucleotide-
linezolid distance, and mutations at distal nucleotides that do not
interact with linezolid directly, in particular, G2576U (19, 30, 56,
66, 69, 97) (Fig. 1D and E) and G2447U (66, 73, 97, 99), confer
significant resistance (Table 1).
Although the effect of a few engineered 23S rRNA mutations
on linezolid susceptibility has been investigated in E. coli by ex-
pressing themutated rRNAon amulticopy plasmid (99), themul-
tiplicity of rRNA operons and heterogeneous ribosome popula-
tions complicates the study of rRNAmutations in many bacteria.
Additional mutations have been investigated in M. smegmatis
strains modified to contain a single rRNA operon (31, 32, 47, 57),
where one model system allows for the introduction of mutations
regardless of whether themutations confer antibiotic resistance or
not (32). This genetic system has been used to test whether rRNA
mutations that confer linezolid resistance in other organisms
(G2576U) also do so in M. smegmatis and to validate rRNA mu-
tations associated with linezolid resistance in the literature with-
out genetic proof (A2503G, G2505A, C2571G, and C2612A) (56).
The study revealed that mutations at some distance from an anti-
biotic binding site can confer resistance and that the same rRNA
mutation can have significantly different effects in different bac-
teria. Moreover, the system has been used to introduce the double
rRNA mutations G2032A-C2499A, G2032A-U2504G, C2055A-
U2504G, and C2055A-A2572U and show that there are strong
synergistic effects on linezolid resistance relative to the effects of
the corresponding single rRNA mutations (56).
The most frequently reported mutation in linezolid-resistant
clinical isolates is 23S RNA G2576U. This mutation has been re-
ported in both staphylococci and enterococci (6, 15, 34, 40, 59, 61,
70, 71, 87, 97, 101), and a clear correlation between the number of
mutated rRNA operons and the linezolid MIC has been found (2,
35, 59). Most reports of the G2576U mutation in clinical isolates
are associated with some form of increased or prolonged linezolid
treatment or with high linezolid usage at the local hospital (29,
84), underscoring the importance of judicious use of linezolid in
clinical settings. Although some studies have documented rever-
sion of the G2576Umutation in the absence of linezolid selection
TABLE 1 23S rRNA linezolid resistance mutations and corresponding nucleotide-linezolid distances
23S rRNA mutationa
D. radiodurans
positionb
LZD distance
(Å)c Origind Organism(s)e Reference(s)
G2032A G2015 9.3 Ec 99
G2032C G2015 9.3 Ec, Ms 56, 99
G2061U G2044 3.0 S Mt 30
A2062C A2045 8.1 S Hh 41
G2447U G2426 6.2 C, S Ec, Ms, Sa, Se 50, 66, 73, 97, 99
C2452U C2431 2.9 S Hh 41
A2453G A2432 6.1 S Hh 41
A2453C A2432 6.1 S Hh 41
C2499U C2478 8.1 S Hh 41
U2500A U2479 7.2 C, S Ec, Sa 62, 66
U2500C U2479 7.2 S Hh 41
A2503G A2482 2.2 S Ms, Sp 19, 56
A2503U A2482 2.2 Ms 47
U2504C U2483 4.5 S Hh, Sa 41, 50
U2504G U2483 4.5 Ms 56
G2505A G2484 2.4 S Em, Es, Ms 8, 56, 69
C2571G C2550 14.7 Ms 56
A2572U A2551 6.6 Ms 56
G2576U G2555 7.9 C, S Ec, Em, Es, Ms, Mt, Sa, Se, Sh, Sp 19, 30, 50, 56, 59, 60, 66, 69, 97
G2608U G2588 15.9 Ec 100
G2608C G2588 15.9 Ec 100
C2612A C2591 17.7 Ms 56
a The nucleotide positions of the mutations are listed according to E. coli numbering.
b The corresponding nucleotide positions in D. radiodurans 23S rRNA.
c The closest approximate distances are given between the corresponding D. radiodurans nucleotides and linezolid (LZD) from the D. radiodurans 50S-linezolid complex X-ray
structure (PDB ID 3DLL) (95).
d Indicates whether a mutation was obtained via in vitro selection (S) or found in clinical isolates (C).
e Abbreviations: Ec, E. coli; Sa, S. aureus; Se, S. epidermidis; Sh, S. haemolyticus; Sp, S. pneumoniae; Es, E. faecalis; Em, E. faecium; Ms,M. smegmatis; Mt,M. tuberculosis;
Hh, H. halobium.
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(62, 87), a recent report showed that the G2576U mutation was
retained in a Staphylococcus haemolyticus isolate even after 30 pas-
sages on antibiotic-free medium (60).
The U2500A (62) and G2447U (97) 23S RNA mutations have
been reported in linezolid-resistant clinical isolates of staphylo-
cocci, and these mutations have been shown to confer linezolid
resistance in in vitro-selected mutants of E. coli and/or M. smeg-
matis (66, 73). Although the U2504Amutation has been reported
in clinical staphylococcal isolates (16, 48, 97), the only U2504
mutation isolated from in vitro selection with linezolid to date is
U2504C (41, 50). Additional mutated positions of 23S rRNA at
G2603U (49, 78, 83) and C2534U (97) have been reported in clin-
ical isolates with reduced linezolid susceptibility, but a direct re-
lationship between these mutations and linezolid resistance is un-
clear.
LINEZOLID RESISTANCE AND A TENTATIVE RELATIONSHIP
TO MUTATIONS IN RIBOSOMAL PROTEINS L3 AND L4
Another type of linezolid resistance determinant has received at-
tention recently, namely, mutations in the ribosomal L3 protein.
Themain part of ribosomal protein L3 is positioned on the surface
of the 50S subunit, but a loop ending in two tips extends into the
PTC (Fig. 1F and Fig. 3). Bacterial L3 mutations have, since 2003,
been associated with resistance to linezolid, tiamulin/valnemulin,
and anisomycin, which all bind to overlapping sites at the PTC.
The first L3 resistancemutation in bacteriawas detected by us inE.
coli by selection with tiamulin, and its role in resistance was veri-
fied by genetic evidence (7).Many studies have since associated L3
mutations with linezolid resistance in S. aureus, Staphylococcus
cohnii, and Staphylococcus epidermidis, and the data are summa-
rized in Table 2.
Locke and colleagues (54) performed a selection study with
bothmethicillin-sensitive andMRSA strains and the oxazolidino-
nes linezolid and TR-700. They obtained variousmutations in 23S
RNA (see above) as well as mutations in L3 and L4 (Table 2), and
apparently only the 23S RNA mutations give high resistance. As
the authors note, directed mutagenesis and heterologous expres-
sion studies are needed to conclusively link these mutations to
oxazolidinone resistance. Nevertheless, the positions of the muta-
tions are correlated with the linezolid binding site in an X-ray
structure and a possible mechanism of structural perturbations is
explained, which, together with the absence of mutations in other
remote peptide regions and in L22 (also sequenced), points to a
role in resistance development.
A search for similar mutations by the same authors in clinical
staphylococci revealed a linezolid-resistant S. aureus strainwith an
L3mutation and a linezolid-resistant S. epidermidis strain with an
L3 mutation plus the G2447U 23S rRNA mutation (53). Another
study identified L3 mutations in the region near the PTC in
linezolid-resistant S. aureus strains from a hospital outbreak in
Spain that also harbored the cfr gene (55). Similarly, sequencing of
selected genes from three clinical isolates from Mexico, with cfr
and linezolid resistance, also revealed L3 and L4 mutations (63)
(Table 2), but the effects of the mutations were not confirmed.
Two of these strains harbored an L101V L3mutation that has also
been detected in a sensitive control strain and is therefore not
considered relevant for linezolid resistance. Ten S. epidermidis
strains from Italy with reduced linezolid susceptibility were inves-
tigated by sequencing the 23S rRNA gene and ribosomal protein
L3, L4, and L22 genes, as well as looking for the cfr gene (65). It was
concluded that the L3 mutations F147L and/or A157R appear to
be responsible for the elevated linezolid MIC values, as adjacent
alterations have been associated with resistance in other strains.
Another recent study (43) reported multiple L3 mutations, but in
most cases, the mutations were together with the 23S rRNA mu-
tation G2576T, which is known to confer linezolid resistance, and
with an L4 insertion. Finally, two newL3mutations have also been
found in linezolid-resistant S. aureus strains from a cystic fibrosis
patient after prolonged drug treatment, where one strain also pos-
sessed the G2576U 23S rRNAmutation (15). It is worthmention-
ing that mutations of L3 at some of the positions mentioned
above, as well as at amino acids close by, are associated with resis-
tance to the pleuromutilins retapamulin and tiamulin (24, 42, 43,
66). As linezolid and the pleuromutilins binds at overlapping sites
at the PTC, these findings support the relationship between L3
mutations and PTC antibiotic resistance in general.
Part of ribosomal protein L4 is also placed relatively close to the
PTC (Fig. 1F) but in the tunnel through which nascent peptides
exit the ribosome. A surveillance study found a slightly linezolid-
resistant S. pneumoniae isolate with a six-nucleotide deletion in
the L4 gene (W65-R66) but with no genetic proof presented
(18). Another surveillance study identified an S. pneumoniae
strain with the same deletion plus a strain with a neighboring
six-nucleotide deletion (K68-G69) in the L4 gene. The deletions
caused a slightly reduced susceptibility to linezolid (MIC change
from 1 g/ml to 4 g/ml) as evidenced by transformations and
were associated with a fitness cost (96). The amino acid deletions
are in the same region as mutations known to be involved inmac-
rolide resistance (26), and as macrolide antibiotics bind to a site
neighboring but not directly overlapping the linezolid binding
site, the effect of the deletions is probably caused by an allosteric
mechanism.
Four different mutations were found in the L4 ribosomal pro-
tein in another study of linezolid-resistant S. epidermidis isolates
(97), but two of these mutations occurred in isolates that also
harbored 23S rRNA mutations. The N158S mutation has been
found among linezolid-sensitive S. epidermidis isolates and is
therefore probably a clonal marker rather than a resistance muta-
tion (97). Also, it has been concluded that L4 K68R is not respon-
sible for resistance in an S. epidermidis study, as it did not increase
resistance when present together with other mutations (65). In
contrast, the L4 mutation K68Q found in the S. aureus selection
study mentioned above was assumed to play a role in resistance
(54), as was an L4 gene mutation in Clostridium perfringens (33).
The L4 mutations related to linezolid resistance are summarized
in Table 2, but the data presented do not present a consistent
FIG3 The sequences of 50S ribosomal proteins L3 and L4 from Staphylococcus
aureus MRSA252. The amino acids highlighted in purple and green corre-
spond to those shown as balls in Fig. 1F. For the L3 sequence, A157 is the
equivalent of E. coli L3 N149.
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pattern and it is not definitively established which changes con-
tribute directly to linezolid resistance.
As sequencing of genes from bacteria exhibiting resistance be-
comes common,manymutations are revealed, but theymight not
all be related to the observed resistance. Somemutations could be
just random changes without significant effect, while others are
likely related to either causing the resistance or accommodating or
sustaining resistance in a synergistic way. This is supported by the
fact that several of the L3 and L4mutations observed in relation to
linezolid resistance are found together with mutations in 23S
rRNA at or near the PTC as mentioned above. Similar possible
synergistic effects have also been reported for other PTC antibiot-
ics in other bacteria such as M. smegmatis (56) and Brachyspira
spp. (28, 68), indicating an interplay between multiple mutations
in relation to resistance, accommodation ofmutations, and fitness
cost. More specific information about the effects of the single and
combined mutations is needed to clarify their detailed interac-
tions.
RESISTANCE CAUSED BY ALTERATIONS
IN 23S rRNA MODIFICATION
It is well established that RNA modifications placed at or near an
antibiotic binding site can affect drug binding to the ribosome.
rRNA is intrinsically modified with methyl groups and pseudou-
ridine residues, mediated by methyltransferase and pseudouri-
dine synthase enzymes, respectively. The modifications are clus-
tered at functional centers on the ribosome and have a collective
importance in optimizing different steps of protein synthesis, al-
though the exact roles of eachmodification are not well described.
Modifications can also be acquired, but to date, the only type of
modification that provides acquired antibiotic resistance is meth-
ylation. Thus, resistance generally occurs either by the inactiva-
tion of an indigenousmethyltransferase or by the acquisition of an
antibiotic resistance methyltransferase.
Several housekeeping modifications at the peptidyl transferase
center are known to affect linezolid susceptibility. The pseudou-
ridylation of 23S rRNA nucleotide 2504 confers resistance to lin-
TABLE 2 Mutations in L3 and L4 that have been associated with linezolid resistance in staphylococci (and one case in Clostridium perfringens) and
corresponding amino acid-linezolid distancesg
Mutation Organism D. radiodurans L3a LZD distanceb Remarksc Reference
L3
F127-H146 S. aureus T113-K132 54
G139R S. aureus G125 25 C, T, 2576T 15
S145 S. aureus S131 25 C 53
S145/H146Y S. aureus S131/K132 25/19.3 C, cfr 55
H146R/M156T Staphylococcus K132/G143 19.3/15.2 C, T, 2215A, 2576T, —,d L4-ins70G 43
H146Q/V154L/A157R Staphylococcus K132/I141/R144 19.3/22.1/7.0 C, T, —,d L4-ins70G, —e 43
F147I Staphylococcus K133 or W134 22.4 or25 C, T, 2215A, 2576T, —,d L4-ins70G 43
F147L/A157R S. epidermidis K133 or W134/R144 22.4 or25/7.0 C, —,d —,e L4-K68R/e 65
G152D S. aureus G139 20.4 2447T 54
G152D S. aureus G139 20.4 C, T 15
G155R S. aureus G142 17.5 54
G155R/M169L S. aureus G142/M156 17.5/25 54
A157R S. epidermidis R144 7.0 C, 2447T 53
S158F/D159Y S. epidermidis K145/T146 13.3/5.4 C, cfr, L3-L101V 63
S158Y/D159Y S. cohnii K145/T146 13.3/5.4 C, cfr, L4-N20S/A133T/V155I 63
M169-G174 S. aureus DM156-G161 C, cfr 55
L4
N20S/A133T/V155I S. cohnii —f C, cfr, L3-S158F/D159Y 63
W65-R66 S. pneumoniae Y59-G60 24.2-21.6 18
W65-R66 S. pneumoniae Y59-G60 24.2-21.6 C, RE 96
K68-G69 S. pneumoniae K62-Q63 11.2-15.1 C, RE 96
K68N S. epidermidis K62 11.2 2576T 97
K68Q S. aureus K62 11.2 54
G71D Clostridium perfringens G65 15.6 33
ins71GGR72 S. epidermidis G65/N66 15.6/16.1 2576T 97
L108S/ins71GGR72 S. epidermidis L102 75 2534T, —e 97
a The L3 sequence from the D. radiodurans 50S X-ray structure (95) used for distance determination has been aligned with L3 from S. aureus, and the amino acids corresponding to
the mutations are listed.
b The distance is the smallest distance from linezolid (LZD) to the corresponding D. radiodurans amino acid.
c Selected additional information. C, from clinical isolates; T, treatment with linezolid; cfr, containing the cfr gene; RE, resistance evidence. Additional resistance determinants are
shown (xxxxN refers to 23S RNA positions corresponding to E. coli 23S RNA, and L3- and L4- indicate additional mutations). See the original references for more details.
d —, L3-L101V, which is not expected to influence linezolid resistance.
e —, L4-N158S, which is not expected to influence linezolid resistance.
f No data for alignment were available.
g Mutations with indications that they are merely strain markers and not relevant for antibiotic resistance are not included, except where they are found together with other
mutations and are then posted under Remarks. The resistance effects vary from very minor effects to substantial resistance, and only in a few cases has there been direct evidence
linking the mutations to resistance. The slash is used when there is more than one mutation. “K133 or W134” indicates that the alignment did not reveal which of these two
positions corresponds to F147.
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ezolid, clindamycin, and tiamulin, suggesting that this modifica-
tion may have evolved as an intrinsic resistance mechanism to
protect bacteria from PTC antibiotics (88). Inactivation of the
spr0333methyltransferase targeting G2445 in 23S rRNA results in
decreased susceptibility to linezolid in S. pneumoniae (3, 19). Like-
wise, mutations inactivating the methyltransferase RlmN, which
methylates the C-2 position of A2503 of 23S rRNA, also lower
linezolid susceptibility in S. aureus (23, 44, 88).
The only known transferable form of linezolid resistance is
conferred by themultiresistance gene cfr, which encodes an rRNA
methyltransferase (39). Cfr adds a methyl group at the C-8 posi-
tion of 23S rRNA nucleotide A2503 (25), the only example of this
modification found in natural RNAs so far. The methylation con-
fers combined resistance to five different classes of antibiotics that
bind at overlapping nonidentical sites at the PTC (58). The resis-
tance is substantial and functions in both Gram-positive and
Gram-negative bacteria. The phenotype is called PhLOPSA, for
resistance to phenicols, lincosamides, oxazolidinones, pleuro-
mutilins, and streptograminA antibiotics. In addition, Cfr confers
significant resistance to selected 16-membered ringmacrolide an-
tibiotics such as josamycin and spiramycin, but not tylosin (81).
The methylation is positioned in the PTC, and its direct interfer-
ence with drug binding is supported by X-ray structures of lin-
ezolid bound to the D. radiodurans and H. marismortui 50S sub-
units (36, 95).
Cfr is related to the RlmN methyltransferases, which add a
methyl group at the C-2 position of 23S rRNA nucleotide A2503
(90). Although the primary activity of Cfr is C-8 methylation,
analysis of a cfr rlmN strain by mass spectrometry showed that
Cfr has a secondary C-2methylation activity, which is the primary
activity of RlmN (25). Phylogenetic analysis of the RlmN/Cfr fam-
ily of proteins suggests that the RlmN subfamily is the ancestral
subfamily and that Cfr likely arose through duplication and hor-
izontal gene transfer (37). Both RlmN and Cfr are radical
S-adenosylmethionine (SAM) enzymes, a superfamily that cata-
lyzes a diverse set of reactions that involve cleavage of unreactive
C-H bonds by a 5=-deoxyadenosyl radical generated by reductive
cleavage of SAM (82, 92). A recent crystal structure of the E. coli
RlmN enzyme (4) and studies on the reaction mechanisms of
RlmN and Cfr show that the methyl group is not transferred di-
rectly from SAM to the RNA but rather through a two-step se-
quence involving intermediate methylation of a conserved cys-
teine residue in the C-terminal domain (27).
The cfr gene was originally discovered on multiresistance plas-
mids isolated during surveillance studies of florfenicol resistance
in Staphylococcus isolates of animal origin (38, 76). The first cfr-
positive clinical strain of methicillin-resistant S. aureus was iso-
lated in 2005, and it had cfr on the chromosome together with the
ermB gene on a transposable genetic element (89). This strain is
notable because these two rRNA methyltransferase genes are lo-
cated on the same operon and their coexpression confers resis-
tance to all clinically relevant antibiotics that target the large ribo-
somal subunit (81). A number of staphylococcal clinical isolates
containing cfr in different genetic contexts and parts of the world
have subsequently been reported (5, 6, 16, 17, 65, 67, 72, 80). In
some instances, a connection between the resistant isolates and
prior linezolid treatment (6, 64) or extensive use of linezolid (72)
can be documented. In addition to staphylococci, the cfr gene has
also been identified in two Bacillus strains isolated from swine
feces (13, 102).Moreover, a recent report detects cfr in an isolate of
Proteus vulgaris, a naturally occurring Gram-negative bacterium
of pigs. The gene is found in a region with homology to a staphy-
lococcal plasmid that is flanked by two IS26 elements and inserted
into the chromosomal fimD gene (93). The presence of cfr on
mobile genetic elements such as plasmids and transposons in dif-
ferent geographical locations strongly suggests that it can be dis-
seminated within the microbial community and spread among
pathogenic bacteria.
DOES LINEZOLID RESISTANCE COME WITH A COST AND
HOW IS IT RELATED TO CROSS-RESISTANCE?
The maintenance and spread of resistance genes are directly re-
lated to their fitness cost. Expression of Cfr in a laboratory strain
has only a small effect on growth rate. Competition experiments
involving wild-type and inactivated Cfr indicate that the small
fitness cost is due not to the C-8methylation but rather to expres-
sion of the protein (45). Similar experiments with strains coex-
pressing the Ermmethyltransferase showed that dimethylation of
23S rRNA position A2058 increases the fitness cost of Cfr-
mediated methylation of A2503 (45). The low fitness cost of cfr is
troubling, as it suggests that cells canmaintain the gene even in the
absence of antibiotic selection. The available data on the fitness
cost of RlmN and the effect of RlmN-mediated methylation on
linezolid susceptibility are confusing and contradictory. It is con-
cluded from one study that an RlmN-deletion strain is outcom-
peted by wild-type cells in the absence of antibiotic selection and
that RlmNmethylation leads to a 2-fold decrease in linezolid sus-
ceptibility in S. aureus (90). In a follow-up study, the authors
concede that the earlier MIC data are inconclusive (44). Subse-
quent competition experiments show that cells with an inacti-
vated rlmN gene outcompeted wild-type cells under linezolid se-
lection (44). This result is corroborated by a study of clinical S.
aureus strains (23) and has implications for resistance develop-
ment in patients undergoing prolonged therapy with linezolid.
The fitness cost of ribosomal mutations varies enormously
from one position to another and is also dependent on the specific
organism. Some bacteria accept mutations at positions in 23S
rRNA that are lethal in others. As mentioned above, a resistance
mutation may be accompanied by other mutations that compen-
sate for deleterious effects or act synergistically to enhance resis-
tance (3). A decrease in growth rates for 23S rRNA mutations at
the PTC is expected because many of the nucleotides are phyloge-
netically conserved and are considered functionally important.
Among the engineered singlemutations inM. smegmatis that have
the most significant effects on linezolid resistance, the mutations
lead to either moderate (A2503G/U and G2447U) or large
(U2504G and G2576U) decreases in growth rate, where the
G2576U mutation has the largest effect and results in 3-fold-
slower growth (47, 56, 57). This is consistent with the fact that
although both theG2447U andG2576Umutations lead to 32-fold
increases in linezolid MIC values, only the G2447Umutation was
isolated by selection in the presence of linezolid (56, 73). Engi-
neered double mutations in M. smegmatis (G2032A-C2499A,
G2032A-U2504G, C2055A-U2504G, and C2055A-A2572U) led
to significantly slower growth compared to the corresponding sin-
glemutations, suggesting thatmultiple changes together have det-
rimental effects in this functionally important region of the ribo-
some (56). The G2576Umutation has been studied extensively in
S. aureus, where a progressive decrease in growth rate is observed
with each additional copy of the mutation (2). However, the abil-
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ity of the mutation to persist in one copy in the absence of antibi-
otic selection and the rapid reemergence ofmultiplemutated cop-
ies upon reexposure to linezolid suggest that a single copy has a
minimal fitness cost (91).
Cross-resistance between PTC antibiotics resulting from 23S
rRNA mutations is not uncommon, but there is no straightfor-
ward relationship between overlapping binding sites and cross-
resistance. Although the different sets of specific mutations, bac-
teria, and antibiotics examined in the literature preclude a detailed
analysis, some patterns have emerged. There is a correlation be-
tween linezolid and chloramphenicol resistance for the single
G2447U, A2503G, U2504G, G2505A, and G2576U mutations in
M. smegmatis (56, 57). However, this correlation does not hold for
the G2032A-U2504G and C2055A-U2504G double mutations,
which both include the U2504Gmutation (56). In the same stud-
ies, no relationship between linezolid, clindamycin, and valnemu-
lin resistance could be observed (56, 57). Cross-resistance between
linezolid and tiamulin has been documented for the G2447U and
U2500A mutations in E. coli and the G2576U mutation in E. coli
and S. aureus (66). The complexity of cross-resistance patterns
between PTC antibiotics is likely due to the unique set of interac-
tions that each bound antibiotic makes with the PTC cavity.
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